Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E: info@isotopeworld.com

Tags

Latest News

Advanced Medical Isotope CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission

(Tue, 14, Feb 2017) >> read more

 

Advanced Medical Isotope CEO Issues Letter to Shareholders Issues Full Status Update, Planned FDA Submission Pathway and Business Plan for 2017 and Beyond

(Wed, 11, Jan 2017) >> read more

 

Advanced Medical Isotope announced today that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board, was named as AMI's interim President and Chief Executive Officer, replacing James Katzaroff.

(Tue, 20, Dec 2016) >> read more

 

Advanced Medical Isotope announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of $527,875.74 USD. 
(Fri, 2, Dec 2016) >> read more

 

 Click here for more news and updates

Social Media


Terms of Use.

Terms of Use:

 

Your use of Advanced Medical Isotope Corporation's (AMIC) website at www.isotopeworld.com constitutes your acceptance of the terms and conditions of use ("Terms") contained herein. We encourage you to read and familiarize yourself with the Terms. Any rights not expressly granted herein are reserved. AMIC reserves the right to change the Terms hereof at any time. Users are responsible for regularly reviewing the Terms. Continued use of the Website following such changes shall constitute user's acceptance of the changes. 

Social Media Disclosure Policy:

 

Investors and others should note that we announce material information to our investors using this investor relations page on our website, quarterly and annual disclosure filings available under ADMD's filings and disclosure at isotopeworld.com, press releases, public conference calls and webcasts. We also use social media channels to announce information about the company and related industry news and opinion. We may choose to communicate material information through social media channels or the information we post on social media channels could be deemed to be material information. Therefore, we encourage investors, the media and others interested in our company to review the information we post on the U.S. social media channels listed below. This list may be updated from time to time:

 

• http://www.twitter.com/isotopeworld

http://www.facebook.com/isotopeworld

http://www.linkedin.com/company/advanced-medical-isotope-corporation

Forward Looking Statements:

 

This website may include forward-looking statements relating to the business, operations, financial condition, and prospects of the Company. You can identify these statements by the use of the words "may", "will", "should", "plans", "expects", "anticipates", "continue", "estimates", "projects", "intends", and similar expressions. These statements involve current expectations, forecasts of future events, and other statements that are not historical facts. Inaccurate assumptions as well as known and unknown risks and uncertainties can affect the accuracy of forward-looking statements and cause actual results to differ materially from those anticipated by these forward-looking statements. Factors that could affect actual future events or results include, but are not limited to, regulatory approval and market acceptance of our brachytherapy technologies; successful implementation of our isotope production expansion plans; our ability to acquire and integrate O-18 and other radioisotope producers and technologies; successful launch of our new cyclotron facility in Los Angeles and production of Molybdenum-99 at the Missouri University Research Reactor; uncertainty as to our ability to continue as a going concern; the likelihood that we will continue to generate operating losses and will have increasing cash requirements; our dependence on our key personnel and consultants; our current customer concentration; and such other risks as are disclosed in our Annual Report on Form 10-K for the Fiscal Year ended December 31, 2012, and as may be disclosed from time to time in our quarterly reports filed with the Securities and Exchange Commission.. You should not rely unduly on these forward-looking statements, which apply only as of the date of this presentation. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

 

The information contained in this website does not purport to be all-inclusive or to contain all information that an investor may require to evaluate the business, operations, financial condition or prospects of the Company. Please see our Annual Report on Form 10-K for the Fiscal Year ended December 31, 2012, for additional information concerning our business, operations, and financial condition.